Fighting Drug addiction

 Here's the story: We sat down with a man who had a harrowing journey with addiction. He began by telling us about his early days in tertiary education, where he would occasionally smoke dagga with friends. However, his focus remained on his studies, and he worked hard to graduate and secure a qualification. After landing a job, he started building a life for himself. He got married, bought a property, and even splurged on a car. Life was good, and he felt like he was on top of the world. But one fateful night, while out with friends, he was introduced to heavier narcotics. At first, the experience was exhilarating. He described it as an elevation from the mild high of dagga to a level 5 high, where he felt invincible and euphoric. The effects would last for days, allowing him to party from Friday to Sunday without sleep. The problem, however, began to manifest on Mondays and Tuesdays every week, when the withdrawal symptoms would kick in, and he'd struggle to function at work....

Israeli study finds 94% drop in symptomatic COVID-19 cases with Pfizer vaccine By Reuters• 14 February 2021 A Pfizer vaccine will be rolled out to every state i

 

JERUSALEM, Feb 14 (Reuters) - Israel's largest healthcare provider on Sunday reported a 94% drop in symptomatic COVID-19 infections among 600,000 people who received two doses of the Pfizer's vaccine in the country's biggest study to date.

Health maintenance organization (HMO) Clalit, which covers more than half of all Israelis, said the same group was also 92% less likely to develop severe illness from the virus.

The comparison was against a group of the same size, with matching medical histories, who had not received the vaccine.

“It shows unequivocally that Pfizer’s coronavirus vaccine is extremely effective in the real world a week after the second dose, just as it was found to be in the clinical study,” said Ran Balicer, Clalit’s chief innovation officer.

He added that the data indicates the Pfizer vaccine, which was developed in partnership with Germany’s BioNTech, is even more effective two weeks or more after the second shot.

Researchers at the Weizmann Institute of Science, who have been tabulating national data, said on Sunday that a sharp decline in hospitalisation and serious illness identified earlier among the first age group to be vaccinated – aged 60 or older – was seen for the first time in those aged 55 and older.

Hospitalisations and serious illness were still rising in younger groups who began vaccinations weeks later.

Israel has been conducting a rapid vaccine rollout and its database offers insights into vaccine effectiveness and at what point countries might attain herd immunity. (Reporting by Ari Rabinovitch and Maayan Lubell Editing by David Goodman)


Comments

Popular posts from this blog

MultiChoice’s BEE scheme trying to find 22 000 shareholders who are missing out on millions

Car Hijackings in South Africa.

Which countries have the world’s largest coal reserves?